Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients

Optimizing treatments for type 2 diabetes mellitus (T2DM) remains an urgent issue. In addition to T2DM treatment strategies, such as glycaemic goals (glucose and glycated haemoglobin ? HbА1c) among different patient populations, the influence of glycaemic variability (GV) on the prognosis of patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Alina Babenko, Elena Ivanovna Krasilnikova, Nikolay Pavlovich Likhonosov, Anna Pavlovna Likhonosova, Elena Nikolaevna Grineva
Format: Article
Language:English
Published: Endocrinology Research Centre 2014-12-01
Series:Сахарный диабет
Subjects:
Online Access:https://www.dia-endojournals.ru/jour/article/view/6406
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849327363452567552
author Alina Babenko
Elena Ivanovna Krasilnikova
Nikolay Pavlovich Likhonosov
Anna Pavlovna Likhonosova
Elena Nikolaevna Grineva
author_facet Alina Babenko
Elena Ivanovna Krasilnikova
Nikolay Pavlovich Likhonosov
Anna Pavlovna Likhonosova
Elena Nikolaevna Grineva
author_sort Alina Babenko
collection DOAJ
description Optimizing treatments for type 2 diabetes mellitus (T2DM) remains an urgent issue. In addition to T2DM treatment strategies, such as glycaemic goals (glucose and glycated haemoglobin ? HbА1c) among different patient populations, the influence of glycaemic variability (GV) on the prognosis of patients with T2DM is also important. According to recent data, GV is associated with cardiovascular complications arising from T2DM. However, although the influence of GV on the development of vascular complications arising from diabetes and underlying mechanisms has been extensively investigated, few studies have investigated the effects of different glucose-lowering medications on GV, and there are even fewer reviews of this topic. This type of analysis is highly relevant, particularly because new classes of antidiabetic medications with potent glucose-dependent insulinotropic effects have been developed. These include groups of drugs that mimic or enhance incretin activity, such as glucagon-like peptide (GLP)-1 analogues/mimetics and dipeptidyl peptidase (DPP)-4 inhibitors. A glucose-dependent mechanism suggests that these groups of antidiabetic medications have beneficial effects on GV. Thus, the current study focusses on the comparative analysis of drugs based on their incretin effects (GLP-1 analogues/mimetics and DPP-4 inhibitors) and оther antidiabetic medications with regard to GV in the patients with T2DM.
format Article
id doaj-art-eff73a7fd76a4619b9da53893fae77f0
institution Kabale University
issn 2072-0351
2072-0378
language English
publishDate 2014-12-01
publisher Endocrinology Research Centre
record_format Article
series Сахарный диабет
spelling doaj-art-eff73a7fd76a4619b9da53893fae77f02025-08-20T03:47:53ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782014-12-01174728010.14341/DM2014472-806454Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patientsAlina Babenko0Elena Ivanovna Krasilnikova1Nikolay Pavlovich Likhonosov2Anna Pavlovna Likhonosova3Elena Nikolaevna Grineva4Federal Almazov Medical Research Centre; St. Petersburg First Pavlov State Medical University, Saint-PetersburgFederal Almazov Medical Research Centre; St. Petersburg First Pavlov State Medical University, Saint-PetersburgSt. Petersburg First Pavlov State Medical University, Saint-PetersburgSt. Petersburg First Pavlov State Medical University, Saint-PetersburgFederal Almazov Medical Research Centre; St. Petersburg First Pavlov State Medical University, Saint-PetersburgOptimizing treatments for type 2 diabetes mellitus (T2DM) remains an urgent issue. In addition to T2DM treatment strategies, such as glycaemic goals (glucose and glycated haemoglobin ? HbА1c) among different patient populations, the influence of glycaemic variability (GV) on the prognosis of patients with T2DM is also important. According to recent data, GV is associated with cardiovascular complications arising from T2DM. However, although the influence of GV on the development of vascular complications arising from diabetes and underlying mechanisms has been extensively investigated, few studies have investigated the effects of different glucose-lowering medications on GV, and there are even fewer reviews of this topic. This type of analysis is highly relevant, particularly because new classes of antidiabetic medications with potent glucose-dependent insulinotropic effects have been developed. These include groups of drugs that mimic or enhance incretin activity, such as glucagon-like peptide (GLP)-1 analogues/mimetics and dipeptidyl peptidase (DPP)-4 inhibitors. A glucose-dependent mechanism suggests that these groups of antidiabetic medications have beneficial effects on GV. Thus, the current study focusses on the comparative analysis of drugs based on their incretin effects (GLP-1 analogues/mimetics and DPP-4 inhibitors) and оther antidiabetic medications with regard to GV in the patients with T2DM.https://www.dia-endojournals.ru/jour/article/view/6406continuous glucose monitoringglycaemic variabilityincretinsglp-1 analogues/mimeticsdpp-4 inhibitors
spellingShingle Alina Babenko
Elena Ivanovna Krasilnikova
Nikolay Pavlovich Likhonosov
Anna Pavlovna Likhonosova
Elena Nikolaevna Grineva
Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
Сахарный диабет
continuous glucose monitoring
glycaemic variability
incretins
glp-1 analogues/mimetics
dpp-4 inhibitors
title Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
title_full Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
title_fullStr Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
title_full_unstemmed Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
title_short Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
title_sort different antihyperglycaemic drug effects on glycaemic variability in type 2 diabetic patients
topic continuous glucose monitoring
glycaemic variability
incretins
glp-1 analogues/mimetics
dpp-4 inhibitors
url https://www.dia-endojournals.ru/jour/article/view/6406
work_keys_str_mv AT alinababenko differentantihyperglycaemicdrugeffectsonglycaemicvariabilityintype2diabeticpatients
AT elenaivanovnakrasilnikova differentantihyperglycaemicdrugeffectsonglycaemicvariabilityintype2diabeticpatients
AT nikolaypavlovichlikhonosov differentantihyperglycaemicdrugeffectsonglycaemicvariabilityintype2diabeticpatients
AT annapavlovnalikhonosova differentantihyperglycaemicdrugeffectsonglycaemicvariabilityintype2diabeticpatients
AT elenanikolaevnagrineva differentantihyperglycaemicdrugeffectsonglycaemicvariabilityintype2diabeticpatients